Study to Understand Novel Biomarkers in Researching Dementia
About this study
The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.
- Condition
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Tested
- Clinical tau PET, Clinical amyloid test, Research blood collection, Cognitive assessments
- Sponsor
- Washington University School of Medicine
Who can join
- Age
- 60 years and older
- Sex
- All sexes
- Healthy volunteers
- Accepted
Inclusion 5
- Minimum age: 60 years
- Study condition: Alzheimer Disease, Mild Cognitive Impairment, Dementia
- At least 60 years of age
- 80% of the newly enrolled clinic-based cohort will have symptoms of forgetfulness, mild cognitive impairment, mild dementia, or Alzheimer's disease as determined by their medical chart and/or provider
- All SEABIRD participants will be invited to participate regardless of their cognitive status
Exclusion 5
- Unable to perform one or more basic activities of daily living (eating, bathing, dressing, ambulating, toileting) due to cognitive impairment
- Uncontrolled hepatitis B, hepatitis C, or HIV at time of blood collection
- Taking a disease-modifying drug for AD at time of enrollment
- Blood transfusion in the last three months
- Unwilling or unable to participate in all study activities
Where
1 site, 1 recruiting
Washington University School of Medicine
St Louis, Missouri, United States
Contact
-
Lisa Soke
314-747-4857 sunbirdstudy@wustl.edu
Potential match only. Final eligibility is determined by the study team.